Pricing for childhood vaccines referencing the current Center for Disease Control and Preventions (CDC) Federal Contract for Vaccine…

GlaxoSmithKline Financial has been awarded a contract by the State of Texas (Contract Number: HHSTX-7-0000415790) effective September 30, 2026, to provide childhood vaccines under pricing that references the current Centers for Disease Control and Prevention Federal Contract for Vaccine and Biologicals (CDC Federal Contract Number: 75D30126D20728). The procurement was executed pursuant to Texas Government Code Section 2155.144, which authorizes the acquisition of goods or services for the benefit of or on behalf of clients served by state agency programs, and Texas Government Code Section 771. The contract falls under the National Institute of Governmental Purchasing category for Serums, Toxoids, and Vaccines (NIGP Code 26980).

The primary deliverable under this award is childhood vaccine supply, with the contract specifically referencing diphtheria, tetanus, and whole-cell pertussis vaccine formulations. While the contract document lists additional pharmaceutical products within the Uniform Standard Product and Service Code classification system—including immunomodulating drugs, hyaluronate compounds, tolvaptan, and thymalfasin—the government description and procurement authority indicate that the contract's primary focus is the provision of childhood vaccines to support Texas state health programs. Specific contract value, annual value, cumulative value, county of performance, and period of performance duration were not provided in the award documentation.